Jefferies Starts Kadmon Holdings (KDMN) at Buy

August 22, 2016 6:59 AM EDT
Get Alerts KDMN Hot Sheet
Price: $6.02 -3.37%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 25 | New: 8
Trade KDMN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies initiates coverage on Kadmon Holdings (NYSE: KDMN) with a Buy rating.

Analyst Biren Amin commented, "Kadmon's lead compound is a ROCK2 inhibitor with a unique mech of action and has reported early signs of efficacy data as a treatment for psoriasis. Further, EFGR inhibitor tesevatinb could address an unmet need in brain mets and unlock an untapped market in polycystic kidney disease."

For an analyst ratings summary and ratings history on Kadmon Holdings click here. For more ratings news on Kadmon Holdings click here.

Shares of Kadmon Holdings closed at $9.97 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment